Lipid-based nanocarriers as an alternative for oral delivery of poorly water-soluble drugs: Peroral and mucosal routes

Current Medicinal Chemistry

Volumn 19, Issue 26, 2012, Pages 4495-4510

  Silva, A C ^a,b   Santos, D ^a   Ferreira, D ^a   Lopes, C M ^b,c  

^a UNIVERSITY OF PORTO   (Portugal)

^b UNIVERSIDADE FERNANDO PESSOA   (Portugal)

^c UNIVERSITY OF TRÁS OS MONTES AND ALTO DOURO   (Portugal)

Author keywords

Gastrointestinal tract; Lipid nanoparticles; Lipid based nanocarriers; Liposomes; Nanoemulsions; Nanostructured lipid carriers; Oral administration; Oral cavity administration; Peroral administration; Poorly water soluble drugs; Solid lipid nanoparticles; Toxicity

Indexed keywords

LIPOSOME; NANOCARRIER; NANOPARTICLE;

DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG SOLUBILITY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MOUTH CAVITY; NANOEMULSION; NONHUMAN; ORAL DRUG ADMINISTRATION; REVIEW;

ADMINISTRATION, ORAL; BIOLOGICAL AVAILABILITY; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMANS; LIPIDS; MOUTH MUCOSA; PHARMACEUTICAL PREPARATIONS; SOLUBILITY; WATER;

EID: 84865758788     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986712803251584     Document Type: Review

References (185)

1. Patel, V.F.; Liu, F.; Brown, M.B. Advances in oral transmucosal drug delivery. J. Control. Release, 2011, 153(2), 106-116.
2. Desai, P.P.; Date, A.A.; Patravale, V.B. Overcoming poor oral bioavailability using nanoparticle formulations - opportunities and limitations. Drug Discov. Today: Technologies, 2012, In press.
3. Chien, J.Y.; Ho, R.J.Y. Drug delivery trends in clinical trials and translational medicine. J. Pharm. Sci., 2008, 97(7), 2543-2547.
4. rd ed.; Swarbrick, J., Ed. Informa Healthcare: New York, 2007; Vol. 2, pp. 1242-1265.
5. DeSesso, J.M.; Jacobson, C.F. Anatomical and physiological parameters affecting gastrointestinal absorption in humans and rats. Food Chem. Toxicol., 2001, 39(3), 209-228.
6. th ed.; McGraw-Hill: New York, 2004.
7. Yáñez, J.A.; Wang, S.W.J.; Knemeyer, I.W.; Wirth, M.A.; Alton, K.B. Intestinal lymphatic transport for drug delivery. Adv. Drug Deliv. Rev., 2011, 63(10-11), 923-942.
8. Rossi, S.; Sandri, G.; Caramella, C.M. Buccal drug delivery: A challenge already won? Drug Discov. Today: Technologies, 2005, 2(1), 59-65.
9. Stenberg, P.; Luthman, K.; Artursson, P. Virtual screening of intestinal drug permeability. J. Control. Release, 2000, 65(1-2), 231-43.
10. Mudie, D.M.; Amidon, G.L.; Amidon, G.E. Physiological parameters for oral delivery and in vitro testing. Mol. Pharm., 2010, 7(5), 1388-1405.
11. McConnell, E.L.; Fadda, H.M.; Basit, A.W. Gut instincts: Explorations in intestinal physiology and drug delivery. Int. J. Pharm., 2008, 364(2), 213-226.
12. Salamat-Miller, N.; Chittchang, M.; Johnston, T.P. The use of mucoadhesive polymers in buccal drug delivery. Adv. Drug Deliv. Rev., 2005, 57(11), 1666-1691.
13. Squier, C.A.; Kremer, M.J. Biology of oral mucosa and esophagus. JNCI Monographs, 2001, 2001(29), 7-15.
14. Silva, A.C.; Santos, D.; Ferreira, D.C.; Souto, E.B. Advances in nanoparticulate carriers for oral delivery of peptides and proteins: Polymeric vs. Lipid nanoparticles. In: Encyclopedia of Nanoscience and Nanotechnology, Nalwa, H.S., Ed. American Scientific Publishers: California, 2010; Vol. 295, pp. 1-14.
15. O'Driscoll, C.M.; Griffin, B.T. Biopharmaceutical challenges associated with drugs with low aqueous solubility-the potential impact of lipid-based formulations. Adv. Drug Deliv. Rev., 2008, 60(6), 617-624.
16. Amidon, G.L.; Lennernäs, H.; Shah, V.P.; Crison, J.R. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res., 1995, 12(3), 413-420.
17. Lopes, C.M.; Oliveira, R.; Silva, A.C. Pharmaceutical approaches for opti- mizing oral anti-inflammatory delivery systems. AIAAMC, 2011, 10(3), 154-165.
18. Torchilin, V.; Siepmann, J.; Siegel, R.A.; Rathbone, M.J. Liposomes in drug delivery In: Fundamentals and Applications of Controlled Release Drug Delivery, Rathbone, M., Ed. Springer US: 2011; pp. 289-328.
19. Chang, H.I.; Yeh, M.K. Clinical development of liposome-based drugs: formulation, characterization, and therapeutic efficacy. Int. J. Nanomedicine, 2012, 7, 49-60.
20. Rajpoot, P.; Pathak, K.; Bali, V. Therapeutic applications of nanoemulsion based drug delivery systems: a review of patents in last two decades. Recent Pat. Drug Deliv. Formul., 2011, 5(2), 163-172.
21. Ganta, S.; Deshpande, D.; Korde, A.; Amiji, M. A review of multifunctional nanoemulsion systems to overcome oral and CNS drug delivery barriers. Mol. Membr. Biol., 2010, 27(7), 260-273.
22. Gaucher, G.v.; Satturwar, P.; Jones, M.-C.; Furtos, A.; Leroux, J.-C. Polymeric micelles for oral drug delivery. Eur. J. Pharm. Biopharm., 2010, 76(2), 147-158.
23. Lukyanov, A.N.; Torchilin, V. P. Micelles from lipid derivatives of water-soluble polymers as delivery systems for poorly soluble drugs. Adv. Drug Deliv. Rev., 2004, 56(9), 1273-1289.
24. Patel, T.; Zhou, J.; Piepmeier, J.M.; Saltzman, W.M. Polymeric nanoparticles for drug delivery to the central nervous system. Adv. Drug Deliv. Rev., 2012, 64(7), 701-705.
25. Ensign, L.M.; Cone, R.; Hanes, J. Oral drug delivery with polymeric nanoparticles: The gastrointestinal mucus barriers. Adv. Drug Deliv. Rev., 2012, 64(6), 557-570.
26. Das, S.; Chaudhury, A. Recent advances in lipid nanoparticle formulations with solid matrix for oral drug delivery. AAPS PharmSciTech, 2011, 12(1), 62-76.
27. Muchow, M.; Maincent, P.; Muller, R.H. Lipid nanoparticles with a solid matrix (SLN, NLC, LDC) for oral drug delivery. Drug Dev. Ind. Pharm., 2008, 34(12), 1394-1405.
28. Gupta, U.; Agashe, H.B.; Asthana, A.; Jain, N.K. A review of in vitro-in vivo investigations on dendrimers: the novel nanoscopic drug carriers. Nanomedicine, 2006, 2(2), 66-73.
29. Mary, J.C. Biological applications of dendrimers. Curr Opin Chem Biol, 2002, 6(6), 742-748.
30. Chen, H.; Khemtong, C.; Yang, X.; Chang, X.; Gao, J. Nanonization strategies for poorly water-soluble drugs. Drug Discov. Today, 2011, 16(7-8), 354-360.
31. Wang, G.D.; Mallet, F.P.; Ricard, F.; Heng, J.Y.Y. Pharmaceutical nanocrys-tals. Curr. Opin. Chem. Engineering, 2012, 1(2), 102-107.
32. Duncan, R.; Gaspar, R. Nanomedicine(s) under the microscope. Mol. Pharm., 2011, 8(6), 2101-2141.
33. Chakraborty, S.; Shukla, D.; Mishra, B.; Singh, S. Lipid-an emerging platform for oral delivery of drugs with poor bioavailability. Eur. J. Pharm. Bio-pharm., 2009, 73(1), 1-15.
34. Porter, C.J.H.; Pouton, C.W.; Cuine, J.F.; Charman, W.N. Enhancing intestinal drug solubilisation using lipid-based delivery systems. Adv. Drug Deliv. Rev., 2008, 60(6), 673-691.
35. Porter, C.J.H.; Charman, W.N. Uptake of drugs into the intestinal lymphatics after oral administration. Adv. Drug Deliv. Rev., 1997, 25(1), 71-89.
36. Colin, W. P. Formulation of poorly water-soluble drugs for oral administration: Physicochemical and physiological issues and the lipid formulation classification system. Eur. J. Pharm. Sci, 2006, 29(3-4), 278-287.
37. Muller, R.H.; Shegokar, R.; Keck, C.M. 20 years of lipid nanoparticles (SLN and NLC): present state of development and industrial applications. Curr. Drug Discov. Technol., 2011, 8(3), 207-227.
38. Hauss, D.J. Oral lipid-based formulations. Adv. Drug Deliv. Rev., 2007, 59(7), 667-676.
39. Bangham, A.D.; Standish, M.M.; Watkins, J.C. Diffusion of univalent ions across the lamellae of swollen phospholipids. J. Mol. Biol., 1965, 13(1), 238-252.
40. Betageri, G.V.; Kulkarni, S.B. Preparation of liposomes. In: Microspheres, microcapsules & liposomes. VI: Preparation & Chemical Application Arshady, R., Ed. Citus Books: London, 1999; Vol. VI, pp. 489-521.
41. Mudshinge, S.R.; Deoreb, A.B.; Patilc, S.; Bhalgat, C.M. Nanoparticles: Emerging carriers for drug delivery. Saudi Pharm. J., 2011, 19, 129-141.
42. Jiskoot, W.; Teerlink, T.; Beuvery, E.C.; Crommelin, D.J. Preparation of liposomes via detergent removal from mixed micelles by dilution. The effect of bilayer composition and process parameters on liposome characteristics. Pharm. Weekbl. Sci., 1986, 8(5), 259-265.
43. Deamer, D.W. Preparation and properties of ether-injection liposomes. Ann. N. Y. Acad. Sci., 1978, 308, 250-258.
44. Szoka, F., Jr.; Papahadjopoulos, D. Procedure for preparation of liposomes with large internal aqueous space and high capture by reverse-phase evaporation. Proc. Natl. Acad. Sci. U S A, 1978, 75(9), 4194-4198.
45. Attama, A.A.; Mpamaugo, V.E. Pharmacodynamics of piroxicam from self-emulsifying lipospheres formulated with homolipids extracted from Capra hircus. Drug Deliv., 2006, 13(2), 133-137.
46. Vemuri, S.; Rhodes, C.T. Development and characterization of a liposome preparation by a pH-gradient method. J. Pharm. Pharmacol., 1994, 46(10), 778-783.
47. Meure, L.A.; Foster, N.R.; Dehghani, F. Conventional and dense gas techniques for the production of liposomes: a review. AAPS Pharm. Sci. Tech., 2008, 9(3), 798-809.
48. Kadimi, U.S.; Balasubramanian, D.R.; Ganni, U.R.; Balaraman, M.; Govindarajulu, V. In vitro studies on liposomal amphotericin B obtained by supercritical carbon dioxide-mediated process. Nanomedicine, 2007, 3(4), 273-280.
49. Vemuri, S.; Rhodes, C.T. Preparation and characterization of liposomes as therapeutic delivery systems: a review. Pharm. Acta Helv., 1995, 70(2), 95-111.
50. Bawarski, W.E.; Chidlowsky, E.; Bharali, D.J.; Mousa, S.A. Emerging nanopharmaceuticals. Nanomedicine, 2008, 4(4), 273-282.
51. Immordino, M.L.; Dosio, F.; Cattel, L. Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int. J. Nanomedicine, 2006, 1(3), 297-315.
52. Jesorka, A.; Orwar, O. Liposomes: technologies and analytical applications. Annu. Rev. Anal. Chem. (Palo Alto Calif), 2008, 1, 801-832.
53. Degim, Z.; Unal, N.; Essiz, D.; Abbasoglu, U. The effect of various liposome formulations on insulin penetration across Caco-2 cell monolayer. Life Sci., 2004, 75(23), 2819-2827.
54. Chen, H.; Langer, R. Oral particulate delivery: status and future trends. Adv. Drug Deliv. Rev., 1998, 34(2-3), 339-350.
55. Ogue, S.; Takahashi, Y.; Onishi, H.; Machida, Y. Preparation of double liposomes and their efficiency as an oral vaccine carrier. Biol. Pharm. Bull., 2006, 29(6), 1223-1228.
56. Zhang, N.; Ping, Q.N.; Huang, G.H.; Xu, W.F. Investigation of lectinmodified insulin liposomes as carriers for oral administration. Int. J. Pharm., 2005, 294(1-2), 247-259.
57. Niu, M.; Lu, Y.; Hovgaard, L.; Wu, W. Liposomes containing glycocholate as potential oral insulin delivery systems: preparation, in vitro characterization, and improved protection against enzymatic degradation. Int. J. Nanomedicine, 2011, 6, 1155-1166.
58. Ipatova, O.M.; Torkhovskaia, T.I.; Medvedeva, N.V.; Prozorovskii, V.N.; Ivanova, N.D.; Shironin, A.V.; Baranova, V.S.; Archakov, A.I. [Bioavailability of oral drug formulations and methods for its improvement]. Biomed. Khim., 2010, 56(1), 101-119.
59. Takeuchi, H.; Matsui, Y.; Sugihara, H.; Yamamoto, H.; Kawashima, Y. Effectiveness of submicron-sized, chitosan-coated liposomes in oral administration of peptide drugs. Int. J. Pharm., 2005, 303(1-2), 160-170.
60. Werle, M.; Takeuchi, H. Chitosan-aprotinin coated liposomes for oral peptide delivery: Development, characterisation and in vivo evaluation. Int. J. Pharm., 2009, 370(1-2), 26-32.
61. Cao, J.; Sun, J.; Wang, X.; Li, X.; Deng, Y. N-trimethyl chitosan-coated multivesicular liposomes for oxymatrine oral delivery. Drug Dev. Ind. Pharm., 2009, 35(11), 1339-1347.
62. Channarong, S.; Chaicumpa, W.; Sinchaipanid, N.; Mitrevej, A. Development and evaluation of chitosan-coated liposomes for oral DNA vaccine: the improvement of Peyer's patch targeting using a polyplex-loaded liposomes. AAPS Pharm. Sci. Tech., 2011, 12(1), 192-200.
63. Fricker, G.; Kromp, T.; Wendel, A.; Blume, A.; Zirkel, J.; Rebmann, H.; Setzer, C.; Quinkert, R.O.; Martin, F.; Muller-Goymann, C. Phospholipids and lipid-based formulations in oral drug delivery. Pharm. Res., 2010, 27(8), 1469-1486.
64. Shukla, A.; Khatri, K.; Gupta, P.N.; Goyal, A.K.; Mehta, A.; Vyas, S.P. Oral immunization against hepatitis B using bile salt stabilized vesicles (bilosomes). J. Pharm. Pharm. Sci., 2008, 11(1), 59-66.
65. Chen, Y.; Lu, Y.; Chen, J.; Lai, J.; Sun, J.; Hu, F.; Wu, W. Enhanced bioavailability of the poorly water-soluble drug fenofibrate by using liposomes containing a bile salt. Int. J. Pharm., 2009, 376(1-2), 153-160.
66. Guan, P.; Lu, Y.; Qi, J.; Niu, M.; Lian, R.; Hu, F.; Wu, W. Enhanced oral bioavailability of cyclosporine A by liposomes containing a bile salt. Int. J. Nanomedicine, 2011, 6, 965-974.
67. Ling, S.S.; Yuen, K.H.; Magosso, E.; Barker, S.A. Oral bioavailability enhancement of a hydrophilic drug delivered via folic acid-coupled liposomes in rats. J. Pharm. Pharmacol., 2009, 61(4), 445-449.
68. Huang, Y.B.; Tsai, M.J.; Wu, P.C.; Tsai, Y.H.; Wu, Y.H.; Fang, J.Y. Elastic liposomes as carriers for oral delivery and the brain distribution of (+)-catechin. J. Drug Target, 19(8), 709-18.
69. Jadon, P.S.; Gajbhiye, V.; Jadon, R.S.; Gajbhiye, K.R.; Ganesh, N. Enhanced oral bioavailability of griseofulvin via niosomes. AAPS Pharm. Sci. Tech., 2009, 10(4), 1186-1192.
70. Bayindir, Z.S.; Yuksel, N. Characterization of niosomes prepared with various nonionic surfactants for paclitaxel oral delivery. J. Pharm. Sci., 2010, 99(4), 2049-2060.
71. Patel, G.B.; Agnew, B.J.; Deschatelets, L.; Fleming, L.P.; Sprott, G.D. In vitro assessment of archaeosome stability for developing oral delivery systems. Int. J. Pharm., 2000, 194(1), 39-49.
72. Omri, A.; Agnew, B.J.; Patel, G.B. Short-term repeated-dose toxicity profile of archaeosomes administered to mice via intravenous and oral routes. Int. J. Toxicol., 2003, 22(1), 9-23.
73. Patel, G.B.; Chen, W. Archaeosome immunostimulatory vaccine delivery system. Curr. Drug Deliv., 2005, 2(4), 407-421.
74. Couvreur, P.; Vauthier, C. Nanotechnology: intelligent design to treat complex disease. Pharm. Res., 2006, 23(7), 1417-1450.
75. Ling, S.S.; Magosso, E.; Khan, N.A.; Yuen, K.H.; Barker, S.A. Enhanced oral bioavailability and intestinal lymphatic transport of a hydrophilic drug using liposomes. Drug Dev. Ind. Pharm., 2006, 32(3), 335-345.
76. Yan-yu, X.; Yun-mei, S.; Zhi-peng, C.; Qi-neng, P. Preparation of silymarin proliposome: a new way to increase oral bioavailability of silymarin in beagle dogs. Int. J. Pharm., 2006, 319(1-2), 162-168.
77. Mayer, L.D.; Bally, M.B.; Hope, M.J.; Cullis, P.R. Techniques for encapsulating bioactive agents into liposomes. Chem. Phys. Lipids, 1986, 40(2-4), 333-345.
78. Payne, N.I.; Timmins, P.; Ambrose, C.V.; Ward, M.D.; Ridgway, F. Prol-iposomes: a novel solution to an old problem. J. Pharm. Sci., 1986, 75(4), 325-329.
79. Rescia, V.C.; Takata, C.S.; de Araujo, P.S.; Bueno da Costa, M.H. Dressing liposomal particles with chitosan and poly(vinylic alcohol) for oral vaccine delivery. J. Liposome Res., 2011, 21(1), 38-45.
80. Karn, P.R.; Vanic, Z.; Pepic, I.; Skalko-Basnet, N. Mucoadhesive liposomal delivery systems: the choice of coating material. Drug Dev. Ind. Pharm., 2011, 37(4), 482-488.
81. Tantisripreecha, C.; Jaturanpinyo, M.; Panyarachun, B.; Sarisuta, N. Development of delayed-release proliposomes tablets for oral protein drug delivery. Drug Dev. Ind. Pharm., 2012, 38(6), 718-727.
82. Li, K.; Chen, D.; Zhao, X.; Hu, H.; Yang, C.; Pang, D. Preparation and investigation of Ulex europaeus agglutinin I-conjugated liposomes as potential oral vaccine carriers. Arch. Pharm. Res., 2011, 34(11), 1899-1907.
83. Li, K.; Zhao, X.; Xu, S.; Pang, D.; Yang, C.; Chen, D. Application of Ulex europaeus agglutinin I-modified liposomes for oral vaccine: Ex Vivo bioad-hesion and in Vivo immunity. Chem. Pharm. Bull. (Tokyo), 2011, 59(5), 618-623.
84. Makhlof, A.; Fujimoto, S.; Tozuka, Y.; Takeuchi, H. In vitro and in vivo evaluation of WGA-carbopol modified liposomes as carriers for oral peptide delivery. Eur. J. Pharm. Biopharm., 2011, 77(2), 216-224.
85. Song, J.; Shi, F.; Zhang, Z.; Zhu, F.; Xue, J.; Tan, X.; Zhang, L.; Jia, X. Formulation and evaluation of celastrol-loaded liposomes. Molecules, 2011, 16(9), 7880-7892.
86. Li, X.; Chen, D.; Le, C.; Zhu, C.; Gan, Y.; Hovgaard, L.; Yang, M. Novel mucus-penetrating liposomes as a potential oral drug delivery system: preparation, in vitro characterization, and enhanced cellular uptake. Int. J. Nanomedicine, 2011, 6, 3151-3162.
87. Chen, H.; Wu, J.; Sun, M.; Guo, C.; Yu, A.; Cao, F.; Zhao, L.; Tan, Q.; Zhai, G. N-trimethyl chitosan chloride-coated liposomes for the oral delivery of curcumin. J. Liposome Res., 2012, 22(2), 100-109.
88. Chu, C.; Tong, S.S.; Xu, Y.; Wang, L.; Fu, M.; Ge, Y.R.; Yu, J.N.; Xu, X.M. Proliposomes for oral delivery of dehydrosilymarin: preparation and evaluation in vitro and in vivo. Acta Pharmacol. Sin., 2011, 32(7), 973-980.
89. Zhang, J.; Yuan, H.; Du, L.; Tnag, Q.; Xu, X. [Study on pharmacokinetics of ferulic acid loaded liposome-in-chitosan-microspheres in rats]. Zhongguo Zhong Ya o Za Zhi, 2011, 36(13), 1751-1754.
90. Vural, I.; Sarisozen, C.; Olmez, S.S. Chitosan coated furosemide liposomes for improved bioavailability. J. Biomed. Nanotechnol., 2011, 7(3), 426-430.
91. Gupta, P.N.; Vyas, S.P. Investigation of lectinized liposomes as M-cell targeted carrier-adjuvant for mucosal immunization. Colloids Surf. B Biointerfaces, 2011, 82(1), 118-125.
92. Cheng, H.C.; Chang, C.Y.; Hsieh, F.I.; Yeh, J.J.; Chien, M.Y.; Pan, R.N.; Deng, M.C.; Liu, D.Z. Effects of tremella-alginate-liposome encapsulation on oral delivery of inactivated H5N3 vaccine. J. Microencapsul., 2011, 28(1), 55-61.
93. Sugihara, H.; Yamamoto, H.; Kawashima, Y.; Takeuchi, H. Effectiveness of submicronized chitosan-coated liposomes in oral absorption of indomethacin. J. Liposome Res., 2012, 22(1), 72-79.
94. Niu, M.; Lu, Y.; Hovgaard, L.; Guan, P.; Tan, Y.; Lian, R.; Qi, J.; Wu, W. Hypoglycemic activity and oral bioavailability of insulin-loaded liposomes containing bile salts in rats: The effect of cholate type, particle size and administered dose. Eur. J. Pharm. Biopharm., 2012, 81(2), 265-272.
95. Tomoyasu, Y.; Yasuda, T.; Maeda, S.; Higuchi, H.; Miyawaki, T. Liposome-encapsulated midazolam for oral administration. J. Liposome Res., 2011, 21(2), 166-172.
96. Li, Z.; Zhang, L.; Sun, W.; Ding, Q.; Hou, Y.; Xu, Y. Archaeosomes with encapsulated antigens for oral vaccine delivery. Vaccine, 2011, 29(32), 5260-5266.
97. Huang, A.; Makhlof, A.; Ping, Q.; Tozuka, Y.; Takeuchi, H. N-trimethyl chitosan-modified liposomes as carriers for oral delivery of salmon calci-tonin. Drug Deliv., 2011, 18(8), 562-569.
98. Parmentier, J.; Thewes, B.; Gropp, F.; Fricker, G. Oral peptide delivery by tetraether lipid liposomes. Int. J. Pharm., 2011, 415(1-2), 150-157.
99. Boonyapiwat, B.; Sarisuta, N.; Kunastitchai, S. Characterization and in vitro evaluation of intestinal absorption of liposomes encapsulating zanamivir. Curr. Drug Deliv., 2011, 8(4), 392-397.
100. Wooster, T.J.; Golding, M.; Sanguansri, P. Impact of oil type on nanoemul-sion formation and Ostwald ripening stability. Langmuir, 2008, 24(22), 12758-12765.
101. Anton, N.; Vandamme, T.F. The universality of low-energy nano-emulsification. Int. J. Pharm., 2009, 377(1-2), 142-147.
102. Anton, N.; Vandamme, T.F. Nano-emulsions and micro-emulsions: clarifications of the critical differences. Pharm. Res., 2011, 28(5), 978-985.
103. Anton, N.; Benoit, J.P.; Saulnier, P. Design and production of nanoparticles formulated from nano-emulsion templates-a review. J. Control. Release, 2008, 128(3), 185-199.
104. Anuchapreeda, S.; Fukumori, Y.; Okonogi, S.; Ichikawa, H. Preparation of lipid nanoemulsions incorporating curcumin for cancer therapy. J. Nanotechn., 2012, 2012, Article ID 270383.
105. Sharma, N.; Bansal, M.; Visht, S.; Sharma, P.K.; Kulkarni, G.T. Nanoemul-sions: a new concept of delivery system. Chronicles of Young Sciences 2010, 1(2), 2-6.
106. Bali, V.; Ali, M.; Ali, J. Study of surfactant combinations and development of a novel nanoemulsion for minimising variations in bioavailability of ezetimibe. Colloids Surf. B Biointerfaces, 2010, 76(2), 410-420.
107. Singh, K.K.; Vingkar, S.K. Formulation, antimalarial activity and biodis-tribution of oral lipid nanoemulsion of primaquine. Int. J. Pharm., 2008, 347(1-2), 136-143.
108. Bakandritsos, A.; Zboril, R.; Bouropoulos, N.; Kallinteri, P.; Favretto, M.E.; Parker, T.L.; Mullertz, A.; Fatouros, D.G. The preparation of magnetically guided lipid based nanoemulsions using self-emulsifying technology. Nanotechnology, 2010, 21(5), 055104.
109. Fatouros, D.G.; Deen, G.R.; Arleth, L.; Bergenstahl, B.; Nielsen, F.S.; Peder-sen, J.S.; Mullertz, A. Structural development of self nano emulsifying drug delivery systems (SNEDDS) during in vitro lipid digestion monitored by small-angle X-ray scattering. Pharm. Res., 2007, 24(10), 1844-1853.
110. Mou, D.; Chen, H.; Du, D.; Mao, C.; Wan, J.; Xu, H.; Yang, X. Hydrogel-thickened nanoemulsion system for topical delivery of lipophilic drugs. Int. J. Pharm., 2008, 353(1-2), 270-276.
111. Surassmo, S.; Min, S.G.; Bejrapha, P.; Choi, M.J. Efficacy of capsicum oleoresin nanocapsules formulation by the modified emulsion-diffusion method. J. Nanosci. Nanotechnol., 2011, 11(1), 642-646.
112. Leong, T.S.; Wooster, T.J.; Kentish, S.E.; Ashokkumar, M. Minimising oil droplet size using ultrasonic emulsification. Ultrason Sonochem, 2009, 16(6), 721-727.
113. Kelmann, R.G.; Kuminek, G.; Teixeira, H.F.; Koester, L.S. Carbamazepine parenteral nanoemulsions prepared by spontaneous emulsification process. Int. J. Pharm., 2007, 342(1-2), 231-9.
114. McClements, D.J.; Rao, J. Food-grade nanoemulsions: formulation, fabrication, properties, performance, biological fate, and potential toxicity. Crit. Rev. Food Sci. Nutr., 2011, 51(4), 285-330.
115. Izquierdo, P.; Esquena, J.; Tadros, T.F.; Dederen, J.C.; Feng, J.; Garcia-Celma, M.J.; Azemar, N.; Solans, C. Phase behavior and nano-emulsion formation by the phase inversion temperature method. Langmuir, 2004, 20(16), 6594-6598.
116. Anton, N.; Gayet, P.; Benoit, J.P.; Saulnier, P. Nano-emulsions and nanocap-sules by the PIT method: an investigation on the role of the temperature cycling on the emulsion phase inversion. Int. J. Pharm., 2007, 344(1-2), 44-52.
117. Chhabra, G.; Chuttani, K.; Mishra, A.K.; Pathak, K. Design and development of nanoemulsion drug delivery system of amlodipine besilate for improvement of oral bioavailability. Drug Dev. Ind. Pharm., 2011, 37(8), 907-916.
118. Brusewitz, C.; Schendler, A.; Funke, A.; Wagner, T.; Lipp, R. Novel polox-amer-based nanoemulsions to enhance the intestinal absorption of active compounds. Int. J. Pharm., 2007, 329(1-2), 173-181.
119. Qhattal, H.S.; Wang, S.; Salihima, T.; Srivastava, S.K.; Liu, X. Nanoemul-sions of cancer chemopreventive agent benzyl isothiocyanate display enhanced solubility, dissolution, and permeability. J. Agric. Food Chem., 2011, 59(23), 12396-12404.
120. Rao, S.V.; Agarwal, P.; Shao, J. Self-nanoemulsifying drug delivery systems (SNEDDS) for oral delivery of protein drugs: II. In vitro transport study. Int. J. Pharm., 2008, 362(1-2), 10-15.
121. Rao, S.V.; Yajurvedi, K.; Shao, J. Self-nanoemulsifying drug delivery system (SNEDDS) for oral delivery of protein drugs: III. In vivo oral absorption study. Int. J. Pharm., 2008, 362(1-2), 16-9.
122. Gao, F.; Zhang, Z.; Bu, H.; Huang, Y.; Gao, Z.; Shen, J.; Zhao, C.; Li, Y. Nanoemulsion improves the oral absorption of candesartan cilexetil in rats: Performance and mechanism. J. Control. Release, 2010, 149(2), 168-174.
123. Shen, Q.; Wang, Y.; Zhang, Y. Improvement of colchicine oral bioavailability by incorporating eugenol in the nanoemulsion as an oil excipient and enhancer. Int. J. Nanomedicine, 2011, 6, 1237-1243.
124. Ganta, S.; Devalapally, H.; Amiji, M. Curcumin enhances oral bioavailability and anti-tumor therapeutic efficacy of paclitaxel upon administration in nanoemulsion formulation. J. Pharm. Sci., 2010, 99(11), 4630-4641.
125. Lin, W.; Hong, J.L.; Shen, G.; Wu, R.T.; Wang, Y.; Huang, M.T.; Newmark, H.L.; Huang, Q.; Khor, T.O.; Heimbach, T.; Kong, A.N. Pharmacokinetics of dietary cancer chemopreventive compound dibenzoylmethane in rats and the impact of nanoemulsion and genetic knockout of Nrf2 on its disposition. Biopharm. Drug Dispos., 2011, 32(2), 65-75.
126. Ge, W.; Li, Y.; Li, Z.S.; Zhang, S.H.; Sun, Y.J.; Hu, P.Z.; Wang, X.M.; Huang, Y.; Si, S.Y.; Zhang, X.M.; Sui, Y.F. The antitumor immune responses induced by nanoemulsion-encapsulated MAGE1-HSP70/SEA complex protein vaccine following peroral administration route. Cancer Immunol. Immunother., 2009, 58(2), 201-208.
127. Ruan, J.; Liu, J.; Zhu, D.; Gong, T.; Yang, F.; Hao, X.; Zhang, Z. Preparation and evaluation of self-nanoemulsified drug delivery systems (SNEDDSs) of matrine based on drug-phospholipid complex technique. Int. J. Pharm., 2009, 386(1-2), 282-290.
128. Xi, J.; Chang, Q.; Chan, C.K.; Meng, Z.Y.; Wang, G.N.; Sun, J.B.; Wang, Y.T.; Tong, H.H.; Zheng, Y. Formulation development and bioavailability evaluation of a self-nanoemulsified drug delivery system of oleanolic acid. AAPS Pharm. Sci. Tech., 2009, 10(1), 172-182.
129. Khandavilli, S.; Panchagnula, R. Nanoemulsions as versatile formulations for paclitaxel delivery: peroral and dermal delivery studies in rats. J. Invest. Dermatol., 2007, 127(1), 154-162.
130. Li, W.; Yi, S.; Wang, Z.; Chen, S.; Xin, S.; Xie, J.; Zhao, C. Self-nanoemulsifying drug delivery system of persimmon leaf extract: Optimization and bioavailability studies. Int. J. Pharm., 2011, 420(1), 161-171.
131. Shafiq, S.; Shakeel, F.; Talegaonkar, S.; Ahmad, F.J.; Khar, R.K.; Ali, M. Development and bioavailability assessment of ramipril nanoemulsion formulation. Eur. J. Pharm. Biopharm., 2007, 66(2), 227-243.
132. Vyas, T.K.; Shahiwala, A.; Amiji, M.M. Improved oral bioavailability and brain transport of Saquinavir upon administration in novel nanoemulsion formulations. Int. J. Pharm., 2008, 347(1-2), 93-101.
133. Parveen, R.; Baboota, S.; Ali, J.; Ahuja, A.; Vasudev, S.S.; Ahmad, S. Oil based nanocarrier for improved oral delivery of silymarin: In vitro and in vivo studies. Int. J. Pharm., 2011, 413(1-2), 245-253.
134. Parveen, R.; Baboota, S.; Ali, J.; Ahuja, A.; Vasudev, S.S.; Ahmad, S. Effects of silymarin nanoemulsion against carbon tetrachloride-induced hepatic damage. Arch. Pharm. Res., 2011, 34(5), 767-774.
135. Mehnert, W.; Mader, K. Solid lipid nanoparticles: production, characterization and applications. Adv. Drug Deliv. Rev., 2001, 47(2-3), 165-196.
136. Müller, R.H.; Mäder, K.; Gohla, S. Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. Eur. J. Pharm. Biopharm., 2000, 50(1), 161-177.
137. Lucks, J.S.; Müller, R.H. Medication vehicles made of solid lipid particles (Solid Lipid Nanospheres - SLN). 1993.
138. Gasco, M.R. Method for producing solid lipid microspheres having a narrow size distribution. 1993.
139. Muller, R.H.; Radtke, M.; Wissing, S.A. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv. Drug Deliv. Rev., 2002, 54 Suppl 1, S131-55.
140. FDA Substances Generally Recognized as Safe. http:// www.accessdata.fda. gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart =182 (accessed 05/02/2012).
141. Müller, R.H.; Keck, C.M. Challenges and solutions for the delivery of biotech drugs-a review of drug nanocrystal technology and lipid nanoparticles. J. Biotechnol., 2004, 113(1-3), 151-170.
142. Silva, A.C.; Amaral, M.H.; Gonzalez-Mira, E.; Santos, D.; Ferreira, D. Solid lipid nanoparticles (SLN) - based hydrogels as potential carriers for oral transmucosal delivery of Risperidone: Preparation and characterization studies. Colloids Surf. B Biointerfaces, 2012, 93, 241-248.
143. Pardeike, J.; Hommoss, A.; Müller, R.H. Lipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical dermal products. Int. J. Pharm., 2009, 366(1-2), 170-184.
144. Nikolic, S.; Keck, C.M.; Anselmi, C.; Müller, R.H. Skin photoprotection improvement: Synergistic interaction between lipid nanoparticles and organic UV filters. Int. J. Pharm., 2011, 414(1-2), 276-284.
145. Souto, E.B.; Almeida, A.J.; Müller, R.H. Lipid nanoparticles (SLN, NLC) for cutaneous drug delivery: structure, protection and skin effects. J Biomed Nanotechnol, 2007, 3(4), 317-331.
146. Bernkop-Schnürch, A. Mucoadhesive systems in oral drug delivery. Drug Discov Today: Technologies, 2005, 2(1), 83-87.
147. Serra, L.; Doménech, J.; Peppas, N.A. Engineering design and molecular dynamics of mucoadhesive drug delivery systems as targeting agents. Eur. J. Pharm. Biopharm., 2009, 71(3), 519-528.
148. Harde, H.; Das, M.; Jain, S. Solid lipid nanoparticles: an oral bioavailability enhancer vehicle. Expert Opin. Drug Deli.v, 2011, 8(11), 1407-1424.
149. Patel, P.A.; Patravale, V.B. AmbiOnp: solid lipid nanoparticles of amphotericin B for oral administration. J. Biomed. Nanotechnol., 2011, 7(5), 632-639.
150. Tsai, M.-J.; Huang, Y.-B.; Wu, P.-C.; Fu, Y.-S.; Kao, Y.-R.; Fang, J.-Y.; Tsai, Y.-H. Oral apomorphine delivery from solid lipid nanoparticles with different monostearate emulsifiers: Pharmacokinetic and behavioral evaluations. J. Pharm. Sci., 2011, 100(2), 547-557.
151. Liu, Y.; Wang, P.; Sun, C.; Zhao, J.; Du, Y.; Shi, F.; Feng, N. Bioadhesion and enhanced bioavailability by wheat germ agglutinin-grafted lipid nanopar-ticles for oral delivery of poorly water-soluble drug bufalin. Int. J. Pharm., 2011, 419(1-2), 260-265.
152. Zhang, Z.; Gao, F.; Bu, H.; Xiao, J.; Li, Y. Solid lipid nanoparticles loading candesartan cilexetil enhance oral bioavailability: in vitro characteristics and absorption mechanism in rats. Nanomedicine, 2012, 8(5), 740-747.
153. Estella-Hermoso de Mendoza, A.; Préat, V.; Mollinedo, F.; Blanco-Prieto, M.J. In vitro and in vivo efficacy of edelfosine-loaded lipid nanoparticles against glioma. J. Control. Release, 2011, 156(3), 421-426.
154. Zhang, T.; Chen, J.; Zhang, Y.; Shen, Q.; Pan, W. Characterization and evaluation of nanostructured lipid carrier as a vehicle for oral delivery of etoposide. Eur. J. Pharm. Sci., 2011, 43(3), 174-179.
155. Alex, A.; Paul, W.; Chacko, A.J.; Sharma, C.P. Enhanced delivery of lopi-navir to the CNS using Compritol®-based solid lipid nanoparticles. Therapeutic Deliv., 2011, 2(1), 25-35.
156. Dong, Z.; Xie, S.; Zhu, L.; Wang, Y.; Wang, X.; Zhou, W. Preparation and in vitro, in vivo evaluations of norfloxacin-loaded solid lipid nanopartices for oral delivery. Drug Deliv., 2011, 18(6), 441-450.
157. Xie, S.; Zhu, L.; Dong, Z.; Wang, Y.; Wang, X.; Zhou, W. Preparation and evaluation of ofloxacin-loaded palmitic acid solid lipid nanoparticles. Int. J. Nanomedicine, 2011, 6, 547-555.
158. Pandita, D.; Ahuja, A.; Lather, V.; Benjamin, B.; Dutta, T.; Velpandian, T.; Khar, R. Development of lipid-based nanoparticles for enhancing the oral bioavailability of paclitaxel. AAPS Pharm. Sci. Tech, 2011, 12(2), 712-722.
159. Luo, C.-F.; Yuan, M.; Chen, M.-S.; Liu, S.-M.; Zhu, L.; Huang, B.-Y.; Liu, X.-W.; Xiong, W. Pharmacokinetics, tissue distribution and relative bioavailability of puerarin solid lipid nanoparticles following oral administration. Int. J. Pharm., 2011, 410(1-2), 138-144.
160. Rawat, M.K.; Jain, A.; Singh, S. Studies on binary lipid matrix based solid lipid nanoparticles of repaglinide: in vitro and in vivo evaluation. J. Pharm. Sci, 2011, 100(6), 2366-2378.
161. Rawat, M.K.; Jain, A.; Singh, S. In vivo and cytotoxicity evaluation of repaglinide-loaded binary solid lipid nanoparticles after oral administration to rats. J. Pharm. Sci., 2011, 100(6), 2406-2417.
162. Silva, A.C.; González-Mira, E.; García, M.L.; Egea, M.A.; Fonseca, J.; Silva, R; Santos, D.; Souto, E.B.; Ferreira, D. Preparation, characterization and biocompatibility studies on risperidone-loaded solid lipid nanoparticles (SLN): high pressure homogenization versus ultrasound. Colloids Surf. B Biointerfaces, 2011, 86(1), 158-165.
163. Silva, A.C.; Lopes, CM.; Fonseca, J.; Soares, M.E.; Santos, D.; Souto, E.B.; Ferreira, D. Risperidone release from solid lipid nanoparticles (SLN): validated HPLC method and modelling kinetic profile. Curr. Pharm. Anal, 2012, 8(2), In press.
164. Shah, M.; Chuttani, K.; Mishra, A.K.; Pathak, K. Oral solid compritol 888 ATO nanosuspension of simvastatin: optimization and biodistribution studies. Drug Dev. Ind. Pharm., 2011, 37(5), 526-537.
165. Abuasal, B.; Lucas, C; Peyton, B.; Alayoubi, A.; Nazzal, S.; Sylvester, P.; Kaddoumi, A. Enhancement of intestinal permeability utilizing solid lipid nanoparticles increases γ-tocotrienol oral bioavailability. Lipids, 2011, 1-9.
166. Das, S.; Ng, W.K.; Kanaujia, P.; Kim, S.; Tan, RB.H. Formulation design, preparation and physicochemical characterizations of solid lipid nanoparticles containing a hydrophobic drug: Effects of process variables. Colloids Surf. B Biointerfaces, 2011, 88(1), 483-489.
167. Olbrich, C; Gessner, A.; Kayser, O.; Müller, R.H. Lipid-Drug-Conjugate (LDC) nanoparticles as novel carrier system for the hydrophilic antitrypanosomal drug diminazenediaceturate. J. Drug Target, 2002, 10(5), 387-396.
168. Wong, H.L.; Bendayan, R; Rauth, A.M.; Wu, X.Y Development of solid lipid nanoparticles containing ionically complexed chemotherapeutic drugs and chemosensitizers. J. Pharm. Sci, 2004, 93(8), 1993-2008.
169. Vega-Villa, K.R; Takemoto, J.K.; Yáñez, J.A.; Remsberg, CM.; Forrest, M.L.; Davies, N.M. Clinical toxicities of nanocarrier systems. Adv. Drug Deliv. Rev, 2008, 60(8), 929-938.
170. Müller, R.H.; Gohla, S.; Keck, CM. State of the art of nanocrystals - Special features, production, nanotoxicology aspects and intracellular delivery. Eur. J. Pharm. Biopharm., 2011, 78(1), 1-9.
171. Souto, E.B.; Martins-Lopes, P.; Lopes, CM.; Gaivao, I.; Silva, A.M.; Guedes-Pinto, H. A note on regulatory concerns and toxicity assessment in lipid-based delivery systems (LDS). J. Biomed. Nanotechnol., 2009, 5(4), 317-322.
172. Meunier, V.; Bourrie, M.; Berger, Y.; Fabre, G. The human intestinal epithelial cell line Caco-2; pharmacological and pharmacokinetic applications. Cell Biol. Toxicol., 1995, 11(3-4), 187-194.
173. van Breemen, R.B.; Li, Y. Caco-2 cell permeability assays to measure drug absorption. Expert Opin. Drug Metab. Toxicol., 2005, 1(2), 175-185.
174. Mosmann, T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods, 1983, 65(1-2), 55-63.
175. Lewinski, N.; Colvin, V.; Drezek, R. Cytotoxicity of nanoparticles. Small, 2008, 4(1), 26-49.
176. Borhade, V.; Pathak, S.; Sharma, S.; Patravale, V. Clotrimazole nanoemulsion for malaria chemotherapy. Part II: Stability assessment, in vivo pharma-codynamic evaluations and toxicological studies. Int. J. Pharm., 2012, 431(1-2), 146-160.
177. Freund, O. Biodistribution and gastrointestinal drug delivery of new lipidic multilamellar vesicles. Drug Deliv., 2001, 8(4), 239-244.
178. Gosangari, S.L.; Watkin, K.L. Effect of preparation techniques on the properties of curcumin liposomes: characterization of size, release and cytotoxicity on a squamous oral carcinoma cell line. Pharm. Dev. Technol., 2010, 17(1), 103-109.
179. Müller, R.H.; Maassen, S.; Schwarz, C.; Mehnert, W. Solid lipid nanoparticles (SLN) as potential carrier for human use: interaction with human granulocytes. J. Control. Release, 1997, 47(3), 261-269.
180. Müller, R.H.; Rühl, D.; Runge, S.; Schulze-Forster, K.; Mehnert, W. Cytotoxicity of solid lipid nanoparticles as a function of the lipid matrix and the surfactant. Pharm. Res., 1997, 14(4), 458-462.
181. Serpe, L.; Catalano, M.G.; Cavalli, R.; Ugazio, E.; Bosco, O.; Canaparo, R.; Muntoni, E.; Frairia, R.; Gasco, M.R.; Eandi, M.; Zara, G.P. Cytotoxicity of anticancer drugs incorporated in solid lipid nanoparticles on HT-29 colorectal cancer cell line. Eur. J. Pharm. Biopharm., 2004, 58(3), 673-680.
182. Olbrich, C.; Schöler, N.; Tabatt, K.; Kayser, O.; Müller, R.H. Cytotoxicity studies of Dynasan 114 solid lipid nanoparticles (SLN) on RAW 264.7 macrophages - impact of phagocytosis on viability and cytokine production. J. Pharm. Pharmacol., 2004, 56(7), 883-891.
183. Schöler, N.; Hahn, H.; Müller, R.H.; Liesenfeld, O. Effect of lipid matrix and size of solid lipid nanoparticles (SLN) on the viability and cytokine production of macrophages. Int. J. Pharm., 2002, 231(2), 167-176.
184. Kristl, J.; Teskac, K.; Milek, M.; Mlinaric-Rascan, I. Surface active stabilizer Tyloxapol in colloidal dispersions exerts cytostatic effects and apoptotic dismissal of cells. Toxicol. Appl. Pharmacol., 2008, 232(2), 218-225.
185. Teskac, K.; Kristl, J. The evidence for solid lipid nanoparticles mediated cell uptake of resveratrol. Int. J. Pharm., 2010, 390(1), 61-69.